Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
Conditions
Interventions
None listed
Sponsors
AIIMS RISHIKESH
Eligibility
Inclusion criteria
Inclusion criteria: The study is designed to include retrospective data on benign and malignant ovarian masses operated from January 2019 till the data of study initiation. It also includes prospective data on benign and 27 malignant ovarian masses who will be operated during an 18-month period since the study initiation.
Exclusion criteria
Exclusion criteria: 1. Those underwent radiotherapy, chemotherapy, targeted drugs, or other anti-tumour therapy prior to surgery 2. had a history of autoimmune diseases or other malignancies 3. had incomplete blood investigation and operative findings 4. Patients with clinical infectious diseases who had a high WBC count 5. Patients with systemic diseases affecting WBC and platelet counts such as immunodeficiency and splenectomy 6. Had borderline ovarian cancer 7. Had undergone any surgery on ovary predominantly at an earlier age 8. Pregnancy with ovarian masses 9. Ovarian masses planned for conservative management
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To compare the values of RDW, MPV, NLR, PLR and LMR in benign and malignant ovarian masses and to identify the optimal cut-off values of NLR, PLR, MLR, RDW and MPV in preoperative prediction of malignant ovarian masses (PRE-OPERATIVE)- at baselineTimepoint: at baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate the prediction performance of these inflammatory markers in different histological types of ovarian malignancy. 2. To identify the sensitivity, specificity, positive predictive value, and negative predictive value of RDW, MPV, NLR, PLR and LMR alone or combined with CA125 in differentiating benign and malignant ovarian masses.Timepoint: PRE-OPERATIVE | — |
Countries
India
Contacts
Public ContactDeepanshi Garg
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, RISHIKESH
Outcome results
None listed